Summary of Observational Studies on Dual Biologic Therapy with Denosumab Indicated for Treatment of Osteoporosis as a Comorbidity of Rheumatoid Arthritis.
Summary of Observational Studies on Dual Biologic Therapy with Denosumab Indicated for Treatment of Osteoporosis as a Comorbidity of Rheumatoid Arthritis.
| Author (Year), Country | Study Design | Dual Therapy (n Patients) | Control Arm (n Patients, if applicable) | Primary Study Outcome | Safety Outcomes of Dual Biologic TX |
|---|---|---|---|---|---|
| Curtis (2015), USA18 | Retrospective Medicare database analysis | Various bDMARDs+DEN (n=1354) | Various bDMARDs+ zoledronic acid (n=4460) | Hospitalized infection rate | No increase of severe infections rate |
| Hasegawa (2016), Japan17 | Retrospective case-control single-center study | Various bDMARDs+DEN (n=40) | Various bDMARDs (n=40) | Radiographic progression (modified Sharp erosion score) | No increase of infections and serious adverse events rate |
| Lau (2018), Canada19 | Retrospective analysis of two rheumatology practices | Various bDMARDs+DEN (n=102) | Various bDMARDs (n=206) | Serious or opportunistic infection rate | Low rate of serious and opportunistic infections in both groups |
| Mirzaei (2021), Iran35 | Retrospective case-control study | Various bDMARDs+DEN (n=40) | Various bDMARDs (n=44) | Rate of infections | Low rate of infections in both groups |